Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Where we are !
View:
Post by Thenorth1990 on Jun 11, 2021 2:56am

Where we are !

https://www.evaluate.com/vantage/articles/analysis/spotlight/next-wave-amyloid-targeting-projects-approaches
Comment by Speyeder999 on Jun 11, 2021 8:42am
Very interesting.  With Acumen Pharmaceuticals going into Phase I and going public very soon, it will be interesting to see what their public offering price and overall market cap evaluation willl be and show Promis stands in comparison.
Comment by Gbathat on Jun 11, 2021 6:44pm
Hopefully we join this group of funded clinical companies soon.  I agree that an IPO of a PHI company would be an excellent benchmark by which to see how undervalued PMN is currently. C'mon PMN, close that deal!!! have a wondeful weekend all.  Thanks for all the insights shared.
Comment by farmerjane on Jun 11, 2021 9:18pm
Agree with who?
Comment by M101 on Jun 11, 2021 2:27pm
yup, Acumen is one to watch now  https://www.fiercebiotech.com/biotech/acumen-pharmaceuticals-files-for-up-to-100m-ipo-two-days-after-biogen-s-alzheimer-s
ProMIS Neurosciences Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities